BackRecursion Pharmaceuticals Overview

Recursion Pharmaceuticals EBIT

EBIT (Earnings Before Interest and Taxes) analysis for RXRX.

Quarterly EBIT

-$148.18M
↑ 22.57% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$599.90M
↓ 5.54% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin